REFERENCES
1. National Comprehensive Cancer Network. Fort Washington PA. c2015. NCCN Practice Guidelines in Oncology: Head and Neck Cancers, version 1. 2015 [updated 2015 Dec 05; cited 2016 Feb 22] Available from http://www.nccn.org/professionals/physician_gls/pdf/head-and-neck.pdf.
2. Unger K, Riaz N, Chen A, Lee NY. Oral Cavity Cancer. In: Lee NY, Liade JL, editors. Target Volume Delineation and Field Setup. A Practical Guide for Conformal and Intensity-Modulated Radiation Therapy. Berlin-Heidelberg: Springer-Verlag; 2013. pp. 35-44.
3. Grégoire V, Ang K, Budach W, Grau C, Hamoir M, Langendijk JA, Lee A, Le QT, MaingonP, Nutting C, O'Sullivan B, Porceddu SV, Lengele B. Delineation of the neck node levels for head and neck tumors: a 2013 update. DAHANCA, EORTC, HKNPCSG, NCIC CTG, NCRI, RTOG, TROG consensus guidelines. Radiother Oncol 2014;110:172-81.
4. Liu SH, Chao KS, Leu YS, Lee JC, Liu CJ, Huang YC, Chang YF, Chen HW, Tsai JT, Chen YJ. Guideline and preliminary clinical practice results for dose specification and target delineation for postoperative radiotherapy for oral cavity cancer. Head Neck 2015;37:933-9.
5. Leclerc M, Lartigau E, Lacornerie T, Daisne JF, Kramar A, Grégoire V. Primary tumor delineation based on (18)FDG PET for locally advanced head and neck cancer treated by chemo-radiotherapy. Radiother Oncol 2015;116:87-93.
6. Brouwer CL, Steenbakkers RJ, Bourhis J, Budach W, Grau C, Grégoire V, van Herk M, Lee A, Maingon P, Nutting C, O'Sullivan B, Porceddu SV, Rosenthal DI, Sijtsema NM, Langendijk JA. CT-based delineation of organs at risk in the head and neck region: DAHANCA, EORTC, GORTEC, HKNPCSG, NCIC CTG, NCRI, NRG Oncology and TROG consensus guidelines. Radiother Oncol 2015;117:83-90.
7. Chao KSC, Mohan R, Marinetti TD, Dong L. Intensity-Modulated Radiation Treatment Techniques and Clinical Applications. In: Halperin EC, Wazer DE, Perez CA, Brady LW, editors. Perez and Brady's Principles and Practice of Radiation Oncology. 6th ed. Philadelphia: Lippincott Williams and Wilkins; 2013. pp. 221-45.
8. Orlandi E, Palazzi M, Pignoli E, Fallai C, Giostra A, Olmi P. Radiobiological basis and clinical results of the simultaneous integrated boost (SIB) intensity modulated radiotherapy (IMRT) for head and neck cancer: a review. Crit Rev Oncol Hematol 2010;73:111-25.
9. Marta GN, Silva V, de Andrade Carvalho H, de Arruda FF, Hanna SA, Gadia R, da Silva JL, Correa SF, Vita Abreu CE, Riera R. Intensity-modulated radiation therapy for head and neck cancer: systematic review and meta-analysis. Radiother Oncol 2014;110:9-15.
10. Beadle BM, Liao KP, Elting LS, Buchholz TA, Ang KK, Garden AS, Guadagnolo BA. Improved survival using intensity-modulated radiation therapy in head and neck cancers: a SEER-Medicare analysis. Cancer 2014;120:702-10.
11. Mazeron JJ, Ardiet JM, Haie-Méder C, Kovács G, Levendag P, Peiffert D, Polo A, Rovirosa A, Strnad V. GEC-ESTRO recommendations for brachytherapy for head and neck squamous cell carcinomas. Radiother Oncol 2009;91:150-6.
12. Lau HY, Hay JH, Flores AD, Threlfall WJ. Seven fractions of twice daily high dose-rate brachytherapy for node-negative carcinoma of the mobile tongue results in loss of therapeutic ratio. Radiother Oncol 1996;39:15-8.
13. Liu Z, Huang S, Zhang D. High dose rate versus low dose rate brachytherapy for oral cancer--a meta-analysis of clinical trials. PLoS One 2013;8:e65423.
14. Nag S, Cano ER, Demanes DJ, Puthawala AA, Vikram B, American Brachytherapy Society. The American Brachytherapy Society recommendations for high-dose-rate brachytherapy for head-and-neck carcinoma. Int J Radiat Oncol Biol Phys 2001;50:1190-8.
15. Petera J, Matula P, Paluska P, Sirak I, Macingova Z, Kasaova L, Frgala T, Hodek M, Vosmik M. High dose rate versus low dose rate brachytherapy in the treatment of tongue carcinoma - a radiobiological study. Neoplasma 2009;56:163-8.
16. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N, Shimizutani K, Inoue T. Brachytherapy for early oral tongue cancer: low dose rate to high dose rate. J Radiat Res 2003;44:37-40.
17. Van Limbergen E, Joiner M, Van der Kogel A, Dörr W. Radiobiology of LDR, HDR, PDR and VLDR Brachytherapy. In: Van Limbergen E, Pötter R, Hoskin P, Baltas D, editors. The GEC ESTRO Handbook of Brachytherapy. 2nd ed (ebook version 1 12/11/2015). Available from: http://www.estro.org/search?type=Activities&q=radiobiology+ldr+hdr&alloptions=on.
18. Grégoire V, Coche E, Cosnard G, Hamoir M, Reychler H. Selection and delineation of lymph node target volumes in head and neck conformal radiotherapy. Proposal for standardizing terminology and procedure based on the surgical experience. Radiother Oncol 2000;56:135-50.
19. Huang SH, Hwang D, Lockwood G, Goldstein DP, O'Sullivan B. Predictive value of tumor thickness for cervical lymph-node involvement in squamous cell carcinoma of the oral cavity: A meta-analysis of reported studies. Cancer 2009;15:1489-97.
20. Sresty NV, Ramanjappa T, Raju AK, Muralidhar KR, Sudarshan G. Acquisition of equal or better planning results with interstitial brachytherapy when compared with intensity-modulated radiotherapy in tongue cancers. Brachytherapy 2010;9:235-8.
21. Studer G, Brown M, Bredell M, Graetz KW, Huber G, Linsenmeier C, Najafi Y, Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in oral cavity cancer: update. Radiat Oncol 2012;7:84.
22. Leung TW, Wong VY, Kwan KH, Ng TY, Wong CM, Tung SY, Leung LC, O SK. High dose rate brachytherapy for early stage oral tongue cancer. Head Neck 2002;24:274-81.
23. Martínez-Monge R, Gómez-Iturriaga A, Cambeiro M, Garrán C, Montesdeoca N, Aristu JJ, Alcalde J. Phase I-II trial of perioperative high-dose-rate brachytherapy in oral cavity and oropharyngeal cancer. Brachytherapy 2009;8:26-33.
24. Guinot JL, Santos M, Tortajada MI, Carrascosa M, Estellés E, Vendrell JB, Muelas R, Chust ML, Mengual JL, Arribas L. Efficacy of high-dose-rate interstitial brachytherapy in patients with oral tongue carcinoma. Brachytherapy 2010;9:227-34.
25. Oota S, Shibuya H, Yoshimura R, Watanabe H, Miura M. Brachytherapy of stage II mobile tongue carcinoma. Prediction of local control and QOL. Radiat Oncol 2006;1:21.
26. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, Matsuura K, Ito K. Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: factors influencing local control and soft tissue complications. Int J Radiat Oncol Biol Phys 1999;44:767-75.
27. Bachaud JM, Delannes M, Allouache N, Benchalal M, Alzieu C, David JM, Serrano E, Daly-Schveitzer NJ. Radiotherapy of stage I and II carcinomas of the mobile tongue and/or floor of the mouth. Radiother Oncol 1994;31:199-206.
28. Inoue T, Inoue T, Yoshida K, Yoshioka Y, Shimamoto S, Tanaka E, Yamazaki H, Shimizutani K, Teshima T, Furukawa S. Phase III trial of high- vs. low-dose-rate interstitial radiotherapy for early mobile tongue cancer. Int J Radiat Oncol Biol Phys 2001;51:171-5.
29. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N, Shimizutani K, Inoue T. Brachytherapy for early oral tongue cancer: low dose rate to high dose rate. J Radiat Res 2003;44:37-40.
30. Yamazaki H, Inoue T, Yoshida K, Yoshioka Y, Furukawa S, Kakimoto N, Shimizutani K. Comparison of three major radioactive sources for brachytherapy used in the treatment of node negative T1-T3 oral tongue cancer: influence of age on outcome. Anticancer Res 2007;27:491-7.
31. Ihara N, Shibuya H, Yoshimura R, Oota S, Miura M, Watanabe H. Interstitial brachytherapy and neck dissection for Stage III squamous cell carcinoma of the mobile tongue. Acta Oncol 2005;44:709-16.
32. Kakimoto N, Inoue T, Inoue T, Murakami S, Furukawa S, Yoshida K, Yoshioka Y, Yamazaki H, Tanaka E, Shimizutani K. Results of low- and high-dose-rate interstitial brachytherapy for T3 mobile tongue cancer. Radiother Oncol 2003;68:123-8.
33. Akiyama H, Yoshida K, Shimizutani K, Yamazaki H, Koizumi M, Yoshioka Y, Kakimoto N, Murakami S, Furukawa S, Ogawa K. Dose reduction trial from 60 Gy in 10 fractions to 54 Gy in 9 fractions schedule in high-dose-rate interstitial brachytherapy for early oral tongue cancer. J Radiat Res 2012;53:722-6.
34. Donath D, Vuong T, Shenouda G, MacDonald B, Tabah R. The potential uses of high-dose-rate brachytherapy in patients with head and neck cancer. Eur Arch Otorhinolaryngol 1995;252:321-4.
35. Inoue T, Inoue T, Yamazaki H, Koizumi M, Kagawa K, Yoshida K, Shiomi H, Imai A, Shimizutani K, Tanaka E, Nose T, Teshima T, Furukawa S, Fuchihata H. High dose rate versus LDR interstitial radiotherapy for carcinoma of the floor of mouth. Int J Radiat Oncol Biol Phys 1998;41:53-8.
36. Matsumoto K, Sasaki T, Shioyama Y, Nakamura K, Atsumi K, Nonoshita T, Ooga S, Yoshitake T, Uehara S, Hirata H, Honda H. Treatment outcome of high-dose-rate interstitial radiation therapy for patients with stage I and II mobile tongue cancer. Jpn J Clin Oncol 2013;43:1012-7.
37. Khalilur R, Hayashi K, Shibuya H. Brachytherapy for tongue cancer in the very elderly is an alternative to external beam radiation. Br J Radiol 2011;84:747-9.
38. Vedasoundaram P, Prasanna AK, Ks R, Selvarajan G, Sinnatamby M, Ramapandian S, Kandasamy S. Role of high dose rate interstitial brachytherapy in early and locally advanced squamous cell carcinoma of buccal mucosa. Springerplus 2014;3:590.
39. Lee SU, Cho KH, Moon SH, Choi SW, Park JY, Yun T, Lee SH, Lim YK, Jeong CY. Clinical outcome of high-dose-rate interstitial brachytherapy in patients with oral cavity cancer. Radiat Oncol J 2014;32:238-46.
40. Tuček L, Petera J, Sirák I, Vošmik M, Doležalová H, Brokešová S, Hodek M, Kašaová L, Paluska P. Hyperfractionated high-dose rate brachytherapy in the treatment of oral tongue cancer. Rep Pract Oncol Radiother 2011;16:243-7.
41. Pernot M, Hoffstetter S, Peiffert D, Aletti P, Lapeyre M, Marchal C, Luporsi E, Bey P, Nancy VL. Role of interstitial brachytherapy in oral and oropharyngeal carcinoma: reflection of a series of 1344 patients treated at the time of initial presentation. Otholaryngol Head Neck Surg 1996;115:519-26.
42. Lefebvre JL, Coche-Dequeant B, Buisset E, Mirabel X, Van JT, Prevost B. Management of early oral cavity cancer. Experience of Centre Oscar Lambret. Eur J Cancer B Oral Oncol 1994;30B:216-20.
43. Mazeron JJ, Simon JM, Le Péchoux C, Crook JM, Grimard L, Piedbois P, Le Bourgeois JP, Pierquin B. Effect of dose rate on local control and complications in definitive irradiation of T1-2 squamous cell carcinomas of mobile tongue and floor of mouth with interstitial iridium-192. Radiother Oncol 1991;21:39-47.
44. Marsiglia H, Haie-Meder C, Sasso G, Mamelle G, Gerbaulet A. Brachytherapy for T1-T2 floor of mouth cancers: the Gustave-Roussy Institute experience. Int J Radiat Oncol Biol Phys 2002;52:1257-63.
45. Dearnaley DP, Dardoufas C, A'Hearn RP, Henk JM. Interstitial irradiation for carcinoma of the tongue and floor of mouth: royal marsden hospital experience 1970-1986. Radiother Oncol 1991;21:183-92.
46. Fujita M, Hirokawa Y, Kashiwado K, Akagi Y, Kashimoto K, Kiriu H, Matsuura K, Ito K. Interstitial brachytherapy for stage I and II squamous cell carcinoma of the oral tongue: factors influencing local control and soft tissue complications. Int J Radiat Oncol Biol Phys 1999;44:767-75.
47. Ihara N, Shibuya H, Yoshimura R, Oota S, Miura M, Watanabe H. Interstitial brachytherapy and neck dissection for Stage III squamous cell carcinoma of the mobile tongue. Acta Oncol 2005;44:709-16.
48. Bourhis J, Overgaard J, Audry H, Ang KK, Saunders M, Bernier J, Horiot JC, Le Maître A, Pajak TF, Poulsen MG, O'Sullivan B, Dobrowsky W, Hliniak A, Skladowski K, Hay JH, Pinto LH, Fallai C, Fu KK, Sylvester R, Pignon JP; Meta-Analysis of Radiotherapy in Carcinomas of Head and neck (MARCH) collaborative group. Hyperfractionated or accelerated radiotherapy in head and neck cancer: a meta-analysis. Lancet 2006;368:843-54.
49. Glenny AM, Furness S, Worthington HV, Conway DI, Oliver R, Clarkson JE, Macluskey M, Pavitt S, Chan KK, Brocklehurst P, CSROC Expert Panel. Interventions for the treatment of oral cavity and oropharyngeal cancer: radiotherapy. Cochrane Database Syst Rev 2010;(12):CD006387.
50. Pignon JP, le Maître A, Maillard E, Bourhis J; MACH-NC Collaborative Group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): an update on 93 randomised trials and 17,346 patients. Radiother Oncol 2009;92:4-14.
51. Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP; MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol 2011;100:33-40.
52. Bourhis J, Sire C, Graff P, Grégoire V, Maingon P, Calais G, Gery B, Martin L, Alfonsi M, Desprez P, Pignon T, Bardet E, Rives M, Geoffrois L, Daly-Schveitzer N, Sen S, Tuchais C, Dupuis O, Guerif S, Lapeyre M, Favrel V, Hamoir M, Lusinchi A, Temam S, Pinna A, Tao YG, Blanchard P, Aupérin A. Concomitant chemoradiotherapy versus acceleration of radiotherapy with or without concomitant chemotherapy in locally advanced head and neck carcinoma (GORTEC 99-02): an open-label phase 3 randomised trial. Lancet Oncol 2012;13:145-53.
53. Nguyen-Tan PF, Zhang Q, Ang KK, Weber RS, Rosenthal DI, Soulieres D, Kim H, Silverman C, Raben A, Galloway TJ, Fortin A, Gore E, Westra WH, Chung CH, Jordan RC, Gillison ML, List M, Le QT. Randomized phase III trial to test accelerated versus standard fractionation in combination with concurrent cisplatin for head and neck carcinomas in the Radiation Therapy Oncology Group 0129 trial: long-term report of efficacy and toxicity. J Clin Oncol 2014;32:3858-66.
54. Martinez-Useros J, Garcia-Foncillas J. The challenge of blocking a wider family members of EGFR against head and neck squamous cell carcinomas. Oral Oncol 2015;51:423-30.
55. Bonner JA, Harari PM, Giralt J, Cohen RB, Jones CU, Sur RK, Raben D, Baselga J, Spencer SA, Zhu J, Youssoufian H, Rowinsky EK, Ang KK. Radiotherapy plus cetuximab for locoregionally advanced head and neck cancer: 5-year survival data from a phase 3 randomised trial, and relation between cetuximab-induced rash and survival. Lancet Oncol 2010;11:21-8.
56. Fletcher GH, Evers WT. Radiotherapeutic management of surgical recurrences and postoperative residuals tumors of the head and neck. Radiology 1970;95:185-8.
57. Marcus RB Jr, Million RR, Cassissi NJ. Postoperative irradiation for squamous cell carcinomas of the head and neck: analysis of time-dose factors related to control above the clavicles. Int J Radiat Oncol Biol Phys 1979;5:1943-49.
58. Lundahl RE, Foote RL, Bonner JA, Suman VJ, Lewis JE, Kasperbauer JL, McCaffrey TV, Olsen KD. Combined neck dissection and postoperative radiation therapy in the management of the high-risk neck: a matched-pair analysis. Int J Radiat Oncol Biol Phys 1998;40:529-34.
59. Lavaf A, Genden EM, Cesaretti JA, Packer S, Kao J. Adjuvant radiotherapy improves overall survival for patients with lymph node-positive head and neck squamous cell carcinoma. Cancer 2008;112:535-43.
60. Kao J, Lavaf F, Teng MS, Huang D, Genden EM. Adjuvant radiotherapy and survival for patients with node-positive head and neck cancer: an analysis by primary site and nodal stage. Int J Radiat Oncol Biol Phys 2008;71:362-70.
61. Hu KS, Quon H, Harrison LB. Management of the neck: radiation therapy and chemotherapy. In: Harrison LB, Sessions RB, Hong WK, editors. Head and Neck Cancer. A Multidisciplinary Approach. 3rd ed. Philadelphia: Lippincot-Williams & Wilkins; 2009. pp. 204-31.
62. Moergel M, Meurer P, Ingel K, Wendt TG, Al-Nawas B. Effectiveness of Postoperative Radiotherapy in Patients with Small Oral and Oropharyngeal Squamous Cell Carcinoma and Concomitant Ipsilateral Singular Cervical Lymph Node Metastasis (pN1). Strahlenther Onkol 2011;187:337-43.
63. Shrime MG, Gullane PJ, Dawson L, Kim J, Gilbert RW, Irish JC, Brown DH, Goldstein DP. The impact of adjuvant radiotherapy on survival in T1-2N1 squamous cell carcinoma of the oral cavity. Arch Otolaryngol Head Neck Surg 2010;136:225-8.
64. Leemans CR, Tiwari T, Nauta JJ, van der Waal L, Snow GB. Regional Lymph node involvement and its signficance in the development of distan metastases in head and neck carcinoma. Cancer 1993;71:452-6.
65. Cooper JS, Pajak TF, Forastiere A, Jacobs J, Fu KK, Ang KK, Laramore GE, Al-Sarraf M. Precisely defining high-risk operable head and neck tumors based on RTOG #83-03 and #88-24: Targets for postoperative radiochemotherapy? Head Neck 1998;20:588-94.
66. Langendijk JA, Slotman BJ, van der Waal I, Doornaert P, Berkof J, Leemans CR. Risk group definition by recursive partitioning analysis of patients with squamous cell head and neck carcinoma treated with surgery and postoperative radiotherapy. Cancer 2005;104:1408-17.
67. Jonkman A, Kaanders JH, Terhaard CH, Hoebers FJ, van den Ende PL, Wijers OB, Verhoef LC, de Jong MA, Leemans CR, Langendijk JA. Multicenter validation of recursive partitioning analysis classification for patients with squamous cell head and neck carcinoma treated with surgery and postperative radiotherapy. Int J Radiat Oncol Biol Phys 2007;68:119-25.
68. Expert Panel on Radiation Oncology-Head and Neck, Salama JK, Saba N, Quon H, Garg MK, Lawson J, McDonald MW, Ridge JA, Smith RV, Yeung AR, Yom SS, Beitler JJ. ACR appropriateness criteria® adjuvant therapy for resected squamous cell carcinoma of the head and neck. Oral Oncol 2011;47:554-9.
69. Bur AM, Lin A, Weinstein GS. Adjuvant radiotherapy for early head and neck squamous cell carcinoma with perineural invasion: a systematic review. Head Neck 2016;38 Suppl 1:E2350-7.
70. Huang J, Barbera L, Brouwers M, Browman G, Mackillop WJ. Does delay instarting treatment affect the outcomes of radiotherapy? a systematic review. J Clin Oncol 2003;21:555-63.
71. Chen Z, King W, Pearcey R, Kerba M, Mackillop WJ. The relationship between waiting time for radiotherapy and clinical outcomes: a systematic review of the literature. Radiother Oncol 2008;87:3-16.
72. van Harten MC, Hoebers FJ, Kross KW, van Werkhoven ED, van den Brekel MW, van Dijk BA. Determinants of treatment waiting times for head and neck cancer in the Netherlands and their relation to survival. Oral Oncol 2015;51:272-8.
73. Peters LJ, Withers HR. Applying radiobiological principles to combined modality treatment of head and neck cancer - the time factor. Int J RadiatOncol Biol Phys 1997;39:831-6.
74. González Ferreira JA, Jaén Olasolo J, Azinovic I, Jeremic B. Effect of radiotherapy delay in overall treatment time on local control andsurvival in head and neck cancer: review of the literature. Rep Pract Oncol Radiother 2015;20:328-39.
75. Ang KK, Trotti A, Brown BW, Garden AS, Foote RL, Morrison WH, Geara FB, Klotch DW, Goepfert H, Peters LJ. Randomized trial addressing risk features and time factors of surgery plus radiotherapy in advanced head-and-neck cancer. Int J Radiat Oncol Biol Phys 2001;51:571-8.
76. Langendijk JA, de Jong MA, Leemans CR, de Bree R, Smeele LE, Doornaert P, Slotman BJ. Postoperative radiotherapy in squamous cell carcinoma of the oral cavity: the importance of the overall treatment time. Int J Radiat Oncol Biol Phys 2003;57:693-700.
77. Peters LJ, Goepfert H, Ang KK, Byers RM, Maor MH, Guillamondegui O, Morrison WH, Weber RS, Garden AS, Frankenthaler RA, Oswald MJ, Brown BW. Evaluation of the dose for postoperative radioation therapy of head and neck cancer: first report of a prospective randomized trial. Int J Radiat Oncol Biol Phys 1993;26:3-11.
78. Winquist E, Oliver T, Gilbert R. Postoperative chemoradiotherapy for advanced squamous cell carcinoma of the head and neck: a systematic review with meta-analysis. Head Neck 2007;29:38-46.
79. Bernier J, Cooper JS, Pajak TF, van Glabbeke M, Bourhis J, Forastiere A, Ozsahin EM, Jacobs JR, Jassem J, Ang KK, Lefèbvre JL. Defining risk levels in locally advanced head and neck cancers: a comparative analysis of concurrent postoperative radiation plus chemotherapy trials of EORTC (#22931) and RTOG (#9501). Head Neck 2005;27:843-50.
80. Cooper JS, Pajak TF, Forastiere AA, Jacobs J, Campbell BH, Saxman SB, Kish JA, Kim HE, Cmelak AJ, Rotman M, Machtay M, Ensley JF, Chao KS, Schultz CJ, Lee N, Fu KK; Radiation Therapy Oncology Group 9501/Intergroup. PostpeRative concurrent radiotherapy and chemotherapy for high risk squamous cell carcinoma of the head and neck. N Engl J Med 2004;350:1937-44.
81. Bernier J, Domenge C, Ozsahin M, Matuszewska K, Lefèbvre JL, Greiner RH, Giralt J, Maingon P, Rolland F, Bolla M, Cognetti F, Bourhis J, Kirkpatrick A, van Glabbeke M, European Organization for Research and Treatment of Cancer Trial 22931. Postoperative irradiation with or without concomitant chemotherapy for locally advanced head and neck cancer. N Engl J Med 2004;350:1945-52.
82. Cooper JS, Zhang Q, Pajak TF, Forastiere AA, Jacobs J, Saxman SB, Kish JA, KimHE, Cmelak AJ, Rotman M, Lustig R, Ensley JF, Thorstad W, Schultz CJ, Yom SS, Ang KK. Long-term follow-up of the RTOG 9501/Intergroup Phase III trial: postoperative concurrent radiation therapy and chemotherapy in high-risk squamous cell carcinoma of the head and neck. Int J Radiat Oncol Biol Phys 2012;84:1198-205.
83. Eisbruch A, Gregoire V. Balancing risk and reward in target delineation for highly conformal radiotherapy in head and neck cancer. Semin Radiat Oncol 2009;19:43-52.
84. Chen AM, Farwell DG, Luu Q, Chen LM, Vijayakumar S, Purdy JA. Marginal misses after postoperative intensity-modulated radiotherapy for head and neck cancer. Int J Radiat Oncol Biol Phys 2011;80:1423-9.
85. Grégoire V, Eisbruch A, Hamoir M, Levendag P. Proposal for the delineation of the nodal CTV in the node-positive and the post-operative neck. Radiother Oncol 2006;79:15-20.
86. Liu SH, Chao KS, Leu YS, Lee JC, Liu CJ, Huang YC, Chang YF, Chen HW, Tsai JT, Chen YJ. Guideline and preliminary clinical practice results for dose specification and target delineation for postoperative radiotherapy for oral cavity cancer. Head Neck 2015;37:933-9.
87. Merlotti A, Alterio D, Vigna-Taglianti R, Muraglia A, Lastrucci L, Manzo R, Gambaro G, Caspiani O, Miccichè F, Deodato F, Pergolizzi S, Franco P, Corvò R, Russi EG, Sanguineti G; Italian Association of Radiation Oncology. Technical guidelines for head and neck cancer IMRT on behalf of the Italian association of radiation oncology - head and neck working group. Radiat Oncol 2014;9:264.
88. Ko HC, Gupta V, Mourad WF, Hu KS, Harrison LB, Som PM, Bakst RL. A contouring guide for head and neck cancers with perineural invasion. Pract Radiat Oncol 2014;4:e247-58.
89. Goineau A, Piot B, Malard O, Ferron C, Lisbona A, Cassagnau E, Delamazure AS, Campion L, Bardet E. Postoperative interstitial brachytherapy for resectable squamous cell carcinoma of the tongue. Brachytherapy 2015;14:71-6.
90. Petera J, Sirák I, Laco J, Kašaová L, Tuček L, Doležalová H. High-dose-rate brachytherapy in early oral cancer with close or positive margins. Brachytherapy 2015;14:77-83.
91. Lapeyre M, Bollet MA, Racadot S, Geoffrois L, Kaminsky MC, Hoffstetter S, Dolivet G, Toussaint B, Luporsi E, Peiffert D. Postoperative brachytherapy alone and combined postoperative radiotherapy and brachytherapy boost for squamous cell carcinoma of the oral cavity, with positive or close margins. Head Neck 2004;26:216-23.
92. Pernot M, Aletti P, Carolus JM, Marquis I, Hoffstetter S, Maaloul F, Peiffert D, Lapeyre M, Luporsi E, Marchal C, Noël A, Bey P. Indications, techniques and results of postoperative brachytherapy in cancer of the oral cavity. Radiother Oncol 1995;35:186-92.
93. Fietkau R, Grabenbauer GG, Iro H, Müller RG, Farmand M, Atendorf-Hofmann A, Sauer R. Interstitial and percutaneous radiotherapy after limited surgery in carcinoma of the oral cavity. Strahlenther Onkol 1991;167:591-8.
94. Chan AK, Huang SH, Le LW, Yu E, Dawson LA, Kim JJ, Cho BC, Bayley AJ, Ringash J, Goldstein D, Chan K, Waldron J, O'Sullivan B, Cummings B, Hope AJ. Postoperative intensity-modulated radiotherapy following surgery for oral cavity squamous cell carcinoma: patterns of failure. Oral Oncol 2013;49:255-60.
95. Hoffmann M, Saleh-Ebrahimi L, Zwicker F, Haering P, Schwahofer A, Debus J, Huber PE, Roeder F. Long term results of postoperative Intensity-Modulated Radiation Therapy (IMRT) in the treatment of Squamous Cell Carcinoma (SCC) located in the oropharynx or oral cavity. Radiat Oncol 2015;10:251.
96. Sher DJ, Thotakura V, Balboni TA, Norris CM Jr, Haddad RI, Posner MR, Lorch J, Goguen LA, Annino DJ, Tishler RB. Treatment of oral cavity squamous cell carcinoma with adjuvant or definitive intensity-modulated radiation therapy. Int J Radiat Oncol Biol Phys 2011;81:e215-22.
97. Gomez DR, Zhung JE, Gomez J, Chan K, Wu AJ, Wolden SL, Pfister DG, Shaha A, Shah JP, Kraus DH, Wong RJ, Lee NY. Intensity-modulated radiotherapy in postoperative treatment of oral cavity cancers. Int J Radiat Oncol Biol Phys 2009;73:1096-103.
98. Chakraborty S, Patil VM, Babu S, Muttath G, Thiagarajan SK. Locoregional recurrences after post-operative volumetric modulated arc radiotherapy (VMAT) in oral cavity cancers in a resource constrained setting: experience and lessons learned. Br J Radiol 2015;88:20140795.
99. Studer G, Brown M, Bredell M, Graetz KW, Huber G, Linsenmeier C, Najafi Y, N Riesterer O, Rordorf T, Schmid S, Glanzmann C. Follow up after IMRT in oral cavity cancer: update. Radiat Oncol 2012;7:84.
100. Collan J, Lundberg M, Vaalavirta L, Bäck L, Kajanti M, Mäkitie A, Tenhunen M, Saarilahti K. Patterns of relapse following surgery and postoperative intensity modulated radiotherapy for oral and oropharyngeal cancer. Acta Oncol 2011;50:1119-25.
101. Geretschläger A, Bojaxhiu B, Crowe S, Arnold A, Manser P, Hallermann W, Aebersold DM, Ghadjar P. Outcome and patterns of failure after postoperative intensity modulated radiotherapy for locally advanced or high-risk oral cavity squamous cell carcinoma. Radiat Oncol 2012;7:175.
102. Yao M, Chang K, Funk GF, Lu H, Tan H, Wacha J, Dornfeld KJ, Buatti JM. The failure patterns of oral cavity squamous cell carcinoma after intensity-modulated radiotherapy-the university of iowa experience. Int J Radiat Oncol Biol Phys 2007;67:1332-41.
